Magdalena Winiarska

Targeting C4d to overcome resistance to antibody-based immunotherapy: an in vitro study

Tumor cells often develop defense mechanisms that render them insensitive to consecutive administrations of therapeutic monoclonal antibodies. This study aimed to produce an antibody that preferentially binds resistant tumor cells and eliminates them by the complement system atta...

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy

CD19-CAR-T cells are a major therapy for relapsed/refractory B-cell malignancies, yet ~50% of patients relapse after infusion. Clinical data suggest that tisa-cel treatment is associated with higher rates of CD19 mutation than axi-cel, though direct comparisons have been lacking....